NCT05710328

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2023-05-10Est. Completion: 2027-05-31

Enrollment target: 235 participants

Locations

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
Los Angeles General Medical Center, Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Saint John's Cancer Institute, Santa Monica, California, United States
Sibley Memorial Hospital, Washington D.C., District of Columbia, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu, Hawaii, United States
Queen's Cancer Cenrer - POB I, Honolulu, Hawaii, United States
Queen's Medical Center, Honolulu, Hawaii, United States
University of Hawaii Cancer Center, Honolulu, Hawaii, United States
Queen's Cancer Center - Kuakini, Honolulu, Hawaii, United States
Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States
Castle Medical Center, Kailua, Hawaii, United States
Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States

Anatomic Stage IV Breast Cancer AJCC v8Hormone Receptor Positive Breast CarcinomaMetastatic Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8

This phase II trial studies how well FDG-PET/CT works in assessing the response of patients with breast cancer that has …

Birmingham, United StatesEst. completion Aug 31, 2027

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.